Speaker describes nanostructured sustained-release drug delivery system

BOSTON — A new device in development for the sustained release of ocular therapies is nanostructured to optimize drug delivery, is completely bioerodible and can be administered intraocularly intramuscularly or subcutaneously, a speaker here said. Focusing on long-term sustained delivery, the delivery system, called Tethadur, is designed for the release of large molecules, including antibodies to the eye, according to Paul Ashton, president and CEO of pSivida.

Full Story →